{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T21:49:25Z","timestamp":1761428965801},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1097\/ftd.0b013e3182577c43","type":"journal-article","created":{"date-parts":[[2012,5,8]],"date-time":"2012-05-08T11:42:32Z","timestamp":1336477352000},"page":"349-355","source":"Crossref","is-referenced-by-count":23,"title":["Risperidone and Total 9-Hydroxyrisperidone in Relation to Prescribed Dose and Other Factors"],"prefix":"10.1097","volume":"34","author":[{"given":"Sally V. J.","family":"Bowskill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon A.","family":"Handley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle S.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxine X.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-18-20210129","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/00007691-200404000-00012","article-title":". Therapeutic monitoring of new antipsychotic drugs.","volume":"26","author":"Hiemke","year":"2004","journal-title":"Ther Drug Monit"},{"key":"R2-18-20210129","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/FTD.0b013e3181dad1fb","article-title":". Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007.","volume":"32","author":"Couchman","year":"2010","journal-title":"Ther Drug Monit"},{"key":"R3-18-20210129","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/JCP.0b013e318221b408","article-title":". Plasma olanzapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1999-2009.","volume":"31","author":"Patel","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"R4-18-20210129","first-page":"415","article-title":"Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia Clin Pharmacokinet.","volume":"50","author":"Schwenger","year":"2011","journal-title":""},{"key":"R5-18-20210129","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":". AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011.","volume":"44","author":"Heimke","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"R6-18-20210129","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jchromb.2008.04.041","article-title":". Validated LC-MSMS methods for the determination of risperidone and the enantiomers of 9-hydroxyrisperidone in human plasma and urine.","volume":"870","author":"De Meulder","year":"2008","journal-title":"J Chromatogr B"},{"key":"R7-18-20210129","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF02245444","article-title":". Regional brain distribution of risperidone and its active metabolite 9-hydroxyrisperidone in the rat.","volume":"114","author":"Van Beijsterveldt","year":"1994","journal-title":"Psychopharmacology (Berl)"},{"key":"R8-18-20210129","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/00007691-199808000-00004","article-title":". Serum concentrations and side effects in psychiatric patients during risperidone therapy.","volume":"20","author":"Olesen","year":"1998","journal-title":"Ther Drug Monit"},{"key":"R9-18-20210129","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.schres.2003.11.001","article-title":". Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia.","volume":"70","author":"Eerdekens","year":"2004","journal-title":"Schizophr Res"},{"key":"R10-18-20210129","first-page":"CD007474","article-title":"Risperidone dose for schizophrenia.","volume":"7","author":"Li","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"R11-18-20210129","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1176\/appi.ajp.163.3.396","article-title":". A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.","volume":"163","author":"Remington","year":"2006","journal-title":"Am J Psychiatr"},{"key":"R12-18-20210129","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0924-9338(00)00536-8","article-title":". Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels.","volume":"16","author":"Mauri","year":"2001","journal-title":"Eur Psychiatr"},{"key":"R16-18-20210129","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00213-010-1852-5","article-title":". Long-acting injectable risperidone and metabolic ratio: a possible index of clinical outcome in treatment-resistant schizophrenic patients.","volume":"210","author":"Volonteri","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"R17-18-20210129","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0379-0738(01)00458-3","article-title":"HPLC of basic drugs on microparticulate strong cation-exchange materials.","volume":"121","author":"Flanagan","year":"2001","journal-title":"Forensic Sci Int"},{"key":"R20-18-20210129","first-page":"443","article-title":". Compliance with SSRI medication during 6 months of treatment for major depression: an evaluation by determination of repeated serum drug concentrations.","volume":"82","author":"Reis","year":"2004","journal-title":"J Affect Disorders"},{"key":"R21-18-20210129","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.pnpbp.2010.02.014","article-title":". Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia.","volume":"34","author":"Yasui-Furukori","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatr"},{"key":"R22-18-20210129","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1055\/s-2007-973836","article-title":". A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.","volume":"40","author":"de Leon","year":"2007","journal-title":"Pharmacopsychiatry"},{"key":"R23-18-20210129","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00007691-200106000-00007","article-title":". Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine.","volume":"23","author":"Spina","year":"2001","journal-title":"Ther Drug Monit"},{"key":"R24-18-20210129","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00007691-200312000-00003","article-title":". Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone.","volume":"25","author":"Aravagiri","year":"2003","journal-title":"Ther Drug Monit"},{"key":"R25-18-20210129","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.clpt.2005.07.007","article-title":". Cytochrome P450 3A inhibitor itraconzole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.","volume":"78","author":"Jung","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R26-18-20210129","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/01.jcp.0000185428.02430.c7","article-title":". Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients.","volume":"25","author":"Saito","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"R27-18-20210129","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0033-3182(10)70664-2","article-title":"The pharmacokinetics of paliperidone versus risperidone.","volume":"51","author":"de Leon","year":"2010","journal-title":"Psychosomatics"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e3182577c43","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:39:41Z","timestamp":1620952781000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201206000-00018"}},"subtitle":["Data From a Therapeutic Drug Monitoring Service, 2002\u20132010"],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e3182577c43","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}